(3) We suggest that targeting M2 macrophages with anti–CSF1/CSF1R agonists and targeting bystander T cells using tumor vaccines or cytokine treatments might play a crucial role in improving the efficacy of HRP treatment. Here, CSF1R is linked to neoplasm.